money moves

Houston software company closes $7 million series A

Houston-based vChain, creator of CodeNotary, has raised $7 million in a series A financing round. Pexels

A Houston tech company that has optimizes a notarization system for coding professionals has closed a multimillion-dollar round of funding.

Houston-based vChain, which created the CodeNotary Open Source code trust solution, has raised $7 million in a series A funding round. Paris-based Elaia Partners led the investment round, and other contributors include Zug, Switzerland-based Bluwat and Seattle-based Acequia Capital.

"CodeNotary today processes over 9 million code and container authentications every single month," says CEO Moshe Bar in a news release. "We believe this is proof that the market demands secure and simple to use trust solutions for the modern DevOps environment."

Bar, who previously founded of XenSource and Qumranet, co-founded vChain with Dennis Zimmer in late 2018. The company released its first product in April of last year, and has a secondary office in Amsterdam.

"With much more at stake both financially and reputationally, companies must act quickly to bring trust and security into their DevOps process," Bar continues. "CodeNotary was created to solve this issue and ensure that only trusted code and data run in production."

The software tool, which is used to ensure code is securely transmitted throughout the entire development to production process, has several platform integrations and works with languages such as JavaScript, Python, Go, Java, and more.

"Our vision is a digital world where every object has a globally unique and meaningful identity," says Zimmer, who serves as CTO, in the release. "For the first time, DevOps teams can completely secure the integrity of their Continuous Integration and Continuous Delivery pipelines. Not just internally, but also across companies, contributors and contractors."

The money raised will be used to continue the development of the tool as the DevOps industry continues to grow within the market.

"The DevOps industry is a rapidly growing billion-dollar market transforming itself very quickly," says Marc Rougier, partner at Elaia, in the release. "The importance of DevOps for any organization is obvious, no matter its size. However, the main reason for hesitation in DevOps transformation is a lack of trust. vChain is the leading solution to bring trust to DevOps and we're thrilled to be a part of it."

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News